Corcept Therapeutics (CORT) Tops Q2 EPS by 10c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 -1.05%
Revenue Growth %: +54.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $117.7 million versus the consensus estimate of $109.6 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
- ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
